Canaccord Genuity Maintains Buy on TELA Bio, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Neutral 59.4%

Neg 0% Neu 59.4% Pos 0%

Canaccord Genuity analyst Caitlin Roberts maintains TELA Bio (NASDAQ:TELA) with a Buy and lowers the price target from $4 to $2.